Santhera Gets Positive Recommendation From NICE For AGAMREE - Quick Facts

(RTTNews) - Santhera Pharmaceuticals (SPHDF.OB) announced that the National Institute for Health and Care Excellence has issued guidance that recommended AGAMREE or vamorolone for use in the National Health Service in England, Wales and Northern Ireland for the treatment of Duchenne muscular dystrophy in patients 4 years of age and older.

The company said, with the positive recommendation, AGAMREE is expected to be funded and available for use within 90 days in England, Wales and Northern Ireland. The company is also progressing through the reimbursement process with the Scottish Medicines Consortium to secure access to AGAMREE for patients in Scotland.

For More Such Health News, visit rttnews.com.